- Home
- RARE vs BOH Comparison
RARE vs BOH Comparison
Compare RARE & BOH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- BOH
- Stock Information
- Founded
- RARE 2010
- BOH 1897
- Country
- RARE United States
- BOH United States
- Employees
- RARE N/A
- BOH N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- BOH Major Banks
- Sector
- RARE Health Care
- BOH Finance
- Exchange
- RARE Nasdaq
- BOH Nasdaq
- Market Cap
- RARE 3.5B
- BOH 2.8B
- IPO Year
- RARE 2014
- BOH N/A
- Fundamental
- Price
- RARE $36.68
- BOH $67.27
- Analyst Decision
- RARE Strong Buy
- BOH Hold
- Analyst Count
- RARE 15
- BOH 6
- Target Price
- RARE $90.53
- BOH $71.67
- AVG Volume (30 Days)
- RARE 1.1M
- BOH 310.8K
- Earning Date
- RARE 07-31-2025
- BOH 07-21-2025
- Dividend Yield
- RARE N/A
- BOH 4.13%
- EPS Growth
- RARE N/A
- BOH N/A
- EPS
- RARE N/A
- BOH 3.56
- Revenue
- RARE $590,689,000.00
- BOH $640,351,000.00
- Revenue This Year
- RARE $18.94
- BOH $15.73
- Revenue Next Year
- RARE $28.93
- BOH $7.97
- P/E Ratio
- RARE N/A
- BOH $19.04
- Revenue Growth
- RARE 33.46
- BOH N/A
- 52 Week Low
- RARE $29.59
- BOH $55.75
- 52 Week High
- RARE $60.37
- BOH $82.70
- Technical
- Relative Strength Index (RSI)
- RARE 51.86
- BOH 55.85
- Support Level
- RARE $36.03
- BOH $66.66
- Resistance Level
- RARE $37.74
- BOH $68.62
- Average True Range (ATR)
- RARE 1.46
- BOH 1.15
- MACD
- RARE -0.01
- BOH 0.27
- Stochastic Oscillator
- RARE 26.56
- BOH 78.77
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About BOH Bank of Hawaii Corporation
Bank of Hawaii Corp provides a broad range of financial products and services predominantly to customers in Hawaii, Guam, and other Pacific Islands. The Bank's subsidiaries are engaged in equipment leasing, securities brokerage, investment advisory services, and providing credit insurance. It is organized into three business segments for management reporting purposes: Consumer Banking, Commercial Banking, and Treasury and Other. Majority of the revenue is generated from Consumer Banking segment which offers a broad range of financial products and services, including loan, deposit and insurance products; private banking and international client banking services; trust services; investment management; and institutional investment advisory services.